Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Foghorn Therapeutics ( (FHTX) ) just unveiled an announcement.
On October 31, 2025, Kristian Humer announced his resignation as Chief Financial Officer of Foghorn Therapeutics, effective November 14, 2025, to pursue other opportunities. His departure was not due to any disagreements with the company. Foghorn Therapeutics also provided a corporate update, highlighting the progress of its various cancer treatment programs. The company is advancing its FHD-909 Phase 1 trial for SMARCA4-mutated cancers, with a focus on non-small cell lung cancer, and is collaborating with Lilly on several oncology programs. Foghorn’s financial position remains strong, with a cash runway into 2028, supporting its ongoing development of selective degrader programs targeting CBP, EP300, and ARID1B for various cancer indications.
The most recent analyst rating on (FHTX) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on Foghorn Therapeutics stock, see the FHTX Stock Forecast page.
Spark’s Take on FHTX Stock
According to Spark, TipRanks’ AI Analyst, FHTX is a Underperform.
Foghorn Therapeutics’ overall stock score is primarily impacted by its challenging financial performance, characterized by persistent losses and high leverage. Technical analysis also indicates bearish momentum, while valuation metrics reflect ongoing financial difficulties. The absence of earnings call data and corporate events further limits the score.
To see Spark’s full report on FHTX stock, click here.
More about Foghorn Therapeutics
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines that treat serious diseases by correcting abnormal gene expression. The company is pioneering precision therapies with broad applicability across cancers, leveraging its expertise in protein degradation and chromatin regulation.
Average Trading Volume: 164,040
Technical Sentiment Signal: Sell
Current Market Cap: $199.6M
For a thorough assessment of FHTX stock, go to TipRanks’ Stock Analysis page.